| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Ardelyx, Inc.$5.28
-0.09 (-1.67%)
C 59Pipeline Score Fair Value Pharma · Commercial
Market Cap
1.36 B
EPS
-0.24
P/E Ratio
-23.17 $
Value Trade
20.60 M
SEC Financials
Q1 2026Dilution Risk
Revenue
94.47 M
R&D Expenses
20.19 M
Operating CF
-32.24 M
Total Assets
504.51 M
Total Liabilities
355.88 M
Equity
148.62 M
D/E Ratio
12,345
-4.23 %
Week
0.49 %
1 Month
-5.86 %
3 Month
10.69 %
6 Month
-11.83 %
5 Year
-57.86 %
All Time
Cash Data
Cash Position
238.07 M
Monthly Burn
10.75 M
Runway
20.1 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
2.34 M
52 Week Range
3.49 - 8.40
% held by Insiders
4 %
% held by Institutions
69.81 %
Enterprise Value
1.33 B
Total Shares
243.05 M
Short %
10.78 %
Float Shares
235.27 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ardelyx, Inc.
356Total events
6Upcoming
84Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 6
Event history 350
Jun 3, 2026
May 8, 2026
◆Oral PresentationXPHOZAHApprovedPresentation
Peer Exchange session on Treating Hyperphosphatemia and Side Effect Management
hyperphosphatemia in chronic kidney disease on dialysissource ↗
May 7, 2026
▲Poster PresentationXPHOZAHApprovedPresentation
Post hoc analysis of NORMALIZE and OPTIMIZE trials on long-term safety of XPHOZAH presented at NKF Spring Clinical Meetings
hyperphosphatemia in chronic kidney disease on dialysissource ↗
May 6, 2026
●Poster PresentationTenapanorApprovedPresentation
Poster presentations at NKF Spring Clinical Meeting 2026
May 5, 2026
◆Oral PresentationIBSRELAApprovedPresentation
Product Theater on IBS-C management at DDW 2026
irritable bowel syndrome with constipation (IBS-C)source ↗
May 2, 2026
◆Poster PresentationIBSRELAApprovedPresentation
Poster presentation on IBS-C treatment patterns at DDW 2026
irritable bowel syndrome with constipation (IBS-C)source ↗
May 2, 2026
●Poster PresentationTenapanorApprovedPresentation
Poster presentations at Digestive Disease Week 2026
Apr 30, 2026
Apr 2026
●Management ChangeCorporate
Appointment of Rajani Dinavahi as CMO and Felecia Ettenberg as CLO
Mar 11, 2026
◆Oral PresentationPresentation
Ardelyx 1x1 meetings at Jefferies 2026 Biotech on the Beach Summit
Mar 10, 2026
◆Oral PresentationPresentation
Ardelyx presentation at Leerink Partners 2026 Global Healthcare Conference
Drug Pipeline Intelligence
C59
Pipeline Score $2.2B
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored1.6x
rNPV / MCap Top 87%
Micro Cap (rank 119 of 911)
Percentile RankArdelyx, Inc. carries a moderate pipeline score (59/100), with $6.5B risk-adjusted pipeline value, led by AZD1722 in Chronic Kidney Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZD1722 Small molecule | Chronic Kidney Disease | Phase 2 | NCT01847092 | 23% | $4.5B | COMPLETED | 154 | - | - | Apr 1, 2015 | - | May 27, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
XPHOZAH PriorityOrphan | chronic kidney disease with hyperphosphatemia on dialysis | — | 2026-05-07 | no clinically meaningful changes in measured serum electrolyte concentrations, other than phosphate reduction Read More | Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings Read More | |
XPHOZAH PriorityOrphan | chronic kidney disease with hyperphosphatemia on dialysis | — | 2026-05-07 | no clinically meaningful changes in measured serum electrolyte concentrations, other than phosphate reduction Read More | Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings Read More | |
XPHOZAH PriorityOrphan | chronic kidney disease with hyperphosphatemia on dialysis | — | 2026-05-07 | no clinically meaningful changes in measured serum electrolyte concentrations, other than phosphate reduction Read More | Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARDXArdelyx to Participate at the Jefferies Global Healthcare Conference 2026
Ardelyx Inc. announced its participation in the Jefferies Global Healthcare Conference 2026, scheduled for June 3 at 9:55 a.m. ET in New York. The company will engage in a fireside chat, which will be accessible via a live webcast. Ardelyx is known for its innovative medicines and has two approved products in the U.S.
Read more →ARDXArdelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
Ardelyx presented a data analysis at the NKF Spring Clinical Meetings, showcasing the long-term safety of XPHOZAH (tenapanor) for managing serum phosphorus in chronic kidney disease patients on dialysis. The analysis indicated no clinically meaningful changes in serum electrolytes, reinforcing the drug's effectiveness. A peer exchange session will further discuss XPHOZAH's mechanism and safety data.
Read more →ARDX▲ +5.3%on this news· ran to +19% by day 3
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year
Ardelyx Inc. reported its financial results for Q1 2026, highlighting a significant increase in total product revenue and continued robust growth for IBSRELA. The company's revenue for IBSRELA amounted to $70.1 million, driven by increased prescription demand. Despite a strong financial position, Ardelyx reported a net loss of $37.6 million during the quarter. The company is focused on advancing its pipeline, including ongoing clinical trials for IBSRELA and the development of the next-generation NHE3 inhibitor, RDX10531.
Read more →ARDXArdelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Ardelyx, Inc. announced that an abstract detailing the long-term effects of XPHOZAH on serum electrolytes will be presented at the NKF Spring Clinical Meetings in May 2026. XPHOZAH is the first phosphate absorption inhibitor approved for adults with chronic kidney disease on dialysis. The company will also sponsor a peer exchange discussing XPHOZAH's efficacy and safety.
Read more →ARDXArdelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
Ardelyx, Inc. announced that an abstract exploring treatment patterns for irritable bowel syndrome with constipation (IBS-C) has been accepted for a poster presentation at the Digestive Disease Week Conference 2026. The company will also sponsor a Product Theater discussing IBS-C management strategies. IBSRELA, Ardelyx's treatment for IBS-C, has shown promise in improving symptoms.
Read more →ARDXArdelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
Ardelyx, Inc. has appointed Felecia W. Ettenberg as Chief Legal Officer, succeeding Elizabeth Grammer. Ettenberg brings over 25 years of legal experience in the biopharmaceutical sector, including a significant tenure at Bristol Myers Squibb. The company aims to leverage her expertise to enhance its legal, compliance, and regulatory operations while continuing to focus on patient needs.
Read more →ARDXArdelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Ardelyx, Inc. announced a conference call for April 30, 2026, to discuss its first quarter financial results and provide a business update. The event will be accessible via a live webcast on the company's website. Ardelyx is known for its innovative medicines, including two approved products and ongoing Phase 3 development.
Read more →ARDXRajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
Ardelyx, Inc. has appointed Dr. Rajani Dinavahi as Chief Medical Officer. With over 20 years of experience in various therapeutic areas, she aims to strengthen the company's pipeline and enhance its medical capabilities. Dr. Dinavahi expressed enthusiasm about joining Ardelyx during a pivotal time for the company.
Read more →ARDX▼ -5.5%on this news
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Ardelyx, Inc. announced the recipients of the 2026 Derek Forfang Patient Advocate Award, honoring individuals who have significantly contributed to advocating for kidney disease patients. Established in 2025, the award commemorates Derek Forfang, a dedicated advocate who passed away due to chronic kidney disease. The recipients include notable figures like Edward Drake II and Markesha Grayson, each recognized for their impactful work in educating and supporting communities. The award presentation will take place at the National Kidney Foundation's Spring Clinical Meetings in New Orleans.
Read more →ARDXArdelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Ardelyx, Inc. announced the publication of a new review article in Therapeutic Advances in Gastroenterology detailing the efficacy of tenapanor, branded as IBSRELA, in providing rapid and sustained relief for adults with irritable bowel syndrome with constipation (IBS-C). The post-hoc analysis of pooled data from three clinical trials indicates that patients can expect noticeable improvements in bowel movement frequency within two weeks, with abdominal symptoms improving significantly within 4-5 weeks. The findings emphasize the importance of continuing therapy for optimal symptom management and offer valuable insights for healthcare providers to better advise patients about treatment expectations.
Read more →ARDX▲ +6.9%on this newsshared move
Ardelyx to Participate in Upcoming Investor Conferences
Ardelyx, Inc. announced its participation in two upcoming investor conferences, including the Leerink Partners 2026 Global Healthcare Conference and the Jefferies 2026 Biotech on the Beach Summit. The company is focused on innovative medicines and has two commercial products approved in the U.S. Additionally, Ardelyx is developing tenapanor for chronic idiopathic constipation and has international agreements for its products.
Read more →ARDX▲ +14.1%on this news
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
Ardelyx has partnered with the LPGA to promote awareness and education around digestive health issues, particularly irritable bowel syndrome with constipation (IBS-C). This multi-year collaboration aims to empower women to discuss their health openly and take proactive steps. The partnership will leverage LPGA's platform to reach a wider audience and encourage informed health decisions.
Read more →ARDXArdelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy
Ardelyx, Inc. reported financial results for 2025, showcasing a significant 73% increase in IBSRELA revenue, reaching $274.2 million. The company anticipates continued growth due to their innovative products and strategies aimed at increasing prescribing depth among healthcare providers. Ardelyx's total revenue for the year was $407.3 million, with XPHOZAH also contributing positively to their revenues. Despite a reported net loss of $61.6 million, Ardelyx is positioned well to capitalize on market opportunities with a strong pipeline of new therapies.
Read more →ARDX▼ -5.1%on this news
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Ardelyx, Inc. announced a conference call scheduled for February 19, 2026, to discuss its financial results for the full year and fourth quarter of 2025. The call will feature commentary from key executives and will be accessible via phone and webcast. Ardelyx continues to focus on developing innovative medicines, including its ongoing Phase 3 development of IBSRELA.
Read more →ARDXArdelyx Receives New Patent for Tenapanor
Ardelyx, Inc. announced the issuance of U.S. Patent No. 12,539,299 for tenapanor formulations, which includes IBSRELA and XPHOZAH. The patent, expiring on November 26, 2042, enhances the company's intellectual property portfolio. CEO Mike Raab emphasized the importance of this patent in extending protections for their innovative medicines. The patent will also be listed in the FDA's Orange Book.
Read more →ARDXFirst Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
Ardelyx, Inc. has initiated the ACCEL Phase 3 clinical trial for IBSRELA, targeting chronic idiopathic constipation (CIC). The trial will enroll approximately 700 patients and evaluate the drug's safety and efficacy over 26 weeks. The first patient has been dosed, marking a significant milestone for the company. Topline data is expected in the second half of 2027.
Read more →ARDX▲ +10.6%on this news
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Ardelyx, Inc. reported approximately $378 million in product revenue for 2025, with IBSRELA generating $274 million, marking a 73% increase from 2024. The company anticipates IBSRELA revenue to reach between $410-430 million in 2026 and aims for $1 billion by 2029. Ardelyx is advancing its pipeline, including a Phase 3 program for IBSRELA in chronic idiopathic constipation.
Read more →ARDXReal-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
Ardelyx, Inc. presented data at ASN Kidney Week showing that XPHOZAH (tenapanor) effectively reduces serum phosphate levels in patients with chronic kidney disease on dialysis. The real-world study indicated that nearly half of the participants experienced a significant reduction in phosphate levels. Additionally, patient satisfaction was high, with many reporting improvements in their condition since starting treatment.
Read more →ARDX▲ +6.3%on this newsshared move
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Ardelyx, Inc. will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025. The event will be accessible via a live webcast on the Ardelyx website, with a replay available for 30 days post-event. Ardelyx focuses on innovative medicines and has two approved products in the U.S.
Read more →ARDX▼ -5.4%on this newsshared move
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
Ardelyx, Inc. announced that its President and CEO, Mike Raab, will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on November 10, 2025. The event will be accessible via a public webcast on the Ardelyx website, with a replay available for 30 days post-event. Ardelyx focuses on developing innovative medicines to address significant unmet medical needs.
Read more →ARDX▲ +21%on this newsshared move
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Ardelyx reported strong financial results for Q3 2025, with product revenue reaching $105.5 million, a 15% increase year-over-year. IBSRELA's revenue surged to $78.2 million, reflecting a 92% growth, prompting the company to raise its revenue guidance for the year. Additionally, Ardelyx announced the development of RDX10531, a next-generation NHE3 inhibitor, signaling its commitment to innovation.
Read more →ARDXArdelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
Ardelyx presented new data on IBSRELA (tenapanor) at the ACG Annual Meeting, highlighting its effectiveness in treating IBS-C. A real-world survey showed 88% patient satisfaction and significant symptom improvement. Additionally, the drug may reduce healthcare visits, indicating a potential benefit to the healthcare system. However, there are warnings regarding dehydration risks.
Read more →ARDXArdelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
Ardelyx, Inc. announced that four abstracts supporting its drug XPHOZAH will be presented at the American Society of Nephrology's Kidney Week from November 5-9, 2025. XPHOZAH is the first phosphate absorption inhibitor approved for chronic kidney disease patients on dialysis. The presentations will cover real-world effectiveness, treatment satisfaction, and bowel movement improvements associated with the drug.
Read more →ARDXArdelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Ardelyx, Inc. announced a conference call scheduled for October 30, 2025, to discuss its third quarter financial results and provide a business update. The call will be accessible via phone and webcast, with a replay available for 30 days. Ardelyx focuses on developing innovative medicines to meet unmet medical needs.
Read more →ARDXArdelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
Ardelyx, Inc. has appointed Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025. Hohenleitner, who has over 30 years of experience in corporate finance, previously served as CFO at Johnson & Johnson's Innovative Medicine North America. Her expertise is expected to enhance Ardelyx's growth and operational excellence as the company expands its commercial success.
Read more →ARDX▲ +16.9%on this news
Ardelyx Announces Changes to the Executive Leadership Team
Ardelyx, Inc. has announced significant changes to its Executive Leadership Team, appointing Edward Conner, M.D. as Chief Medical Officer and John Bishop, Ph.D. as Chief Technical Operations Officer. The company is also preparing for the departure of Justin Renz, the Chief Financial and Operations Officer, who will assist in the transition until a successor is appointed. These changes aim to strengthen Ardelyx's leadership and support its growth strategy.
Read more →ARDXArdelyx Reports Second Quarter 2025 Financial Results and Provides Business Update Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year
Ardelyx, Inc. reported strong financial results for the second quarter of 2025, achieving total revenues of $97.7 million, a 33% increase from the previous year. The company noted remarkable growth in sales of its product IBSRELA, which reached $65.0 million with an 84% year-over-year rise. Despite these positive figures, Ardelyx faced challenges with XPHOZAH, which saw a revenue decline due to changes in Medicare coverage. The company has raised its revenue expectations for IBSRELA for the full year, reflecting confidence in its commercial strategy.
Read more →ARDXArdelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
Ardelyx, Inc. has announced that it will hold a conference call on August 4, 2025, to discuss its financial results for the second quarter of 2025. The company aims to provide insights into its business performance during the call. Ardelyx is known for its innovative, first-in-class medicines, with two commercial products approved in the U.S. Additionally, the company has international agreements for its key product, tenapanor, enhancing its global outreach.
Read more →ARDXArdelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
Ardelyx, Inc. has announced the appointment of Mike Kelliher as Chief Business Officer and James P. Brady as Chief Human Resources Officer. Kelliher, previously Executive Vice President of Corporate Development and Strategy, will now oversee lifecycle management and business development. Brady, who has extensive HR experience, is expected to play a key role in talent development and organizational growth. The leadership changes are aimed at accelerating the company’s momentum and enhancing its capacity to meet medical needs.
Read more →ARDXArdelyx to Participate at the Jefferies Global Healthcare Conference 2025
Ardelyx, Inc. (Nasdaq: ARDX) has announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025, scheduled for June 4, 2025. This event underscores Ardelyx's commitment to innovation in biopharmaceuticals, particularly in meeting unmet medical needs. The company's product offerings include two approved medications in the U.S., IBSRELA and XPHOZAH, which also have international commercialization agreements in place.
Read more →ARDX▲ +5.8%on this news
Ardelyx Presents Data Supporting IBSRELA (tenapanor) at Digestive Disease Week 2025 Conference
Ardelyx, Inc. presented promising data on IBSRELA (tenapanor) during the Digestive Disease Week 2025 in San Diego. The data includes positive findings on the safety and tolerability of IBSRELA in pediatric patients, as well as insights from a real-world survey about the financial burden faced by IBS patients. The company emphasizes its ongoing commitment to enhancing the treatment of irritable bowel syndrome with constipation (IBS-C). All poster presentations are available for public access.
Read more →ARDXArdelyx Reports First Quarter 2025 Financial Results and Provides Business Update Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million
Ardelyx, Inc. reported its first-quarter financial results for 2025, showcasing a total revenue of $74.1 million, representing a 61% increase year-over-year. IBSRELA net product sales reached $44.4 million with a growth rate of 57%, while XPHOZAH generated $23.4 million, marking a 30% increase outside of prior period adjustments. The company's cash position stood at $214 million, despite a net loss of $41.1 million due to increased operating expenses. Ardelyx remains focused on strategic growth and pipeline development for its products.
Read more →ARDXArdelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
Ardelyx, Inc. has appointed Dr. Merdad Parsey to its board of directors, highlighting his extensive experience in the biopharma industry. Dr. Parsey's appointment is seen as pivotal for the company's future growth, especially in expanding its pipeline of innovative medicines. With over 25 years of experience, he brings valuable insights from his previous leadership roles at notable biopharmaceutical companies. Both Ardelyx's CEO and Dr. Parsey express confidence in advancing the company's mission to address unmet medical needs for patients.
Read more →ARDXArdelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
Ardelyx, Inc. has announced that three abstracts focusing on their product IBSRELA (tenapanor) will be presented at the Digestive Disease Week 2025 conference in San Diego. The submissions highlight aspects such as the safety of tenapanor in pediatric patients and its pharmacokinetic studies, as well as a survey on the financial burden of IBS in America. The company will also sponsor a Product Theater discussing new treatment mechanisms for IBS-C, aiming to bolster clinical practices in managing the condition.
Read more →ARDXArdelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Ardelyx, Inc. has announced a conference call scheduled for May 1, 2025, to discuss the financial results for the first quarter of 2025. The call will be held at 4:30 p.m. Eastern Time and will also provide a business update. Ardelyx has two commercial products approved in the United States and is working with various international partners for the development and commercialization of its lead product, tenapanor.
Read more →ARDXArdelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
Ardelyx, Inc. announced that an abstract detailing a post-hoc analysis of the OPTIMIZE Study for XPHOZAH (tenapanor) has been accepted for presentation at the upcoming National Kidney Foundation Spring Clinical Meetings. This study evaluated methods to optimize phosphorus management in patients with chronic kidney disease on dialysis. XPHOZAH is approved as add-on therapy for patients not adequately responding to phosphate binders. Ardelyx will also sponsor a session focused on hyperphosphatemia management during the conference.
Read more →ARDXArdelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Ardelyx, Inc. has announced the recipients of the inaugural Derek Forfang Patient Advocate Award on World Kidney Day. The award honors individuals who have made significant contributions to advocating for patients suffering from chronic kidney disease. The first awardees include Mary Baliker, Erich Ditschman, Nichole Jefferson, Curtis Warfield, and David M. White, each recognized for their tireless work in raising awareness and improving the healthcare experience for kidney patients. The recipients will be formally honored during a reception at the upcoming National Kidney Foundation Spring Clinical Meetings.
Read more →ARDX▼ -10.1%on this news· ran to -20% by day 1shared move
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2
Ardelyx, Inc. has reported its financial results for the fourth quarter and full year of 2024, highlighting significant revenue growth. Total revenue reached $333.6 million, bolstered by strong sales of its products IBSRELA and XPHOZAH. IBSRELA alone generated $158.3 million in net product sales, while XPHOZAH brought in $160.9 million in its first year of sales. Despite a net loss of $39.1 million, the company's cash position improved to $250.1 million, supporting future growth.
Read more →ARDXArdelyx to Present at the TD Cowen 45th Annual Health Care Conference
Ardelyx, Inc. announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3, 2025, in Boston. The company's management will present at the event, which attendees can access via a live webcast. Ardelyx aims to provide innovative medicinal solutions for significant health needs, and it currently has two approved products in the U.S., along with international commercialization agreements.
Read more →ARDXArdelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Ardelyx, Inc. will hold a conference call on February 20, 2025, to discuss its financial results for the full year and fourth quarter of 2024. The call will provide a business update and allow investors to engage directly with company representatives. Ardelyx is known for its innovative medicines, particularly two products approved in the U.S. under the brand names IBSRELA and XPHOZAH. The call will be available via live audio webcast and will be archived for future access.
Read more →ARDX▲ +16%on this news
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
Ardelyx, Inc. has reported significant commercial success for its products, achieving approximately $319 million in U.S. net product sales revenue for 2024. The company anticipates further growth in 2025, with projections for IBSRELA to surpass $1 billion in annual sales and XPHOZAH to reach $750 million. Ardelyx maintains a solid cash position of about $250 million, which supports its strategic focus on growth and operational improvements. However, access to XPHOZAH is now limited under Medicare Part D and safety warnings exist for both products concerning specific patient demographics.
Read more →ARDXArdelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Ardelyx, Inc. has announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. This event will showcase Ardelyx's ongoing commitment to develop first-in-class medications that address unmet medical needs. The conference aims to provide insights into the company's advancements and future endeavors. Ardelyx currently offers two commercial products approved in the U.S., both utilizing the active ingredient tenapanor.
Read more →ARDXArdelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
Ardelyx, Inc. will participate in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. Chief Financial and Operations Officer Justin Renz and Chief Commercial Officer Eric Foster will engage in a fireside chat during the event. The company aims to showcase its mission of developing innovative medicines addressing significant unmet medical needs. Ardelyx is known for its commercial products approved in the U.S., including IBSRELA and XPHOZAH, and has ongoing international agreements for its products.
Read more →ARDX▼ -20.5%on this news
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Ardelyx, Inc. confirmed that a U.S. District Court granted a motion to dismiss a lawsuit involving the inclusion of XPHOZAH in the Medicare ESRD PPS. This decision allows the Centers for Medicare and Medicaid Services to implement a policy starting January 1, 2025, that may restrict access to important phosphate lowering therapies for dialysis patients. The company's CEO expressed concern over the implications for dialysis patients' access to necessary care and reiterated Ardelyx's commitment to advocating for patient access. Additionally, the court's ruling has been met with disappointment from Ardelyx's leadership as they explore further options related to the lawsuit.
Read more →ARDXArdelyx to Participate at the 2024 Jefferies London Healthcare Conference
Ardelyx, Inc. has announced its participation in the 2024 Jefferies London Healthcare Conference, with key executives set to engage in a fireside chat. The event will take place on November 19, 2024, and will be accessible via webcast through the Ardelyx website. The company continues to focus on innovative medicines that address significant unmet medical needs, boasting two approved products in the U.S. and various global commercialization agreements.
Read more →ARDXArdelyx Reports Third Quarter 2024 Financial Results and Provides Business Update IBSRELA generates $40.6 million in net product sales revenue Company expects full year 2024 IBSRELA net sales revenue to be between $145 a
Ardelyx, Inc. reported its third quarter 2024 financial results, highlighting significant revenue growth from its products IBSRELA and XPHOZAH. IBSRELA generated $40.6 million in net product sales, reflecting a 15% increase from the previous quarter, while XPHOZAH achieved $51.5 million in sales. The company ended the quarter with a healthy cash position of approximately $190 million, indicating solid financial backing for continued operations. However, Ardelyx reported a net loss of $0.8 million and rising operational costs, which may impact future profitability.
Read more →ARDXArdelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
Ardelyx, Inc. presented results from its IBS in America 2024 supplemental survey at the ACG Annual Meeting, revealing that 90% of IBS-C patients experience significant negative impacts on their lives. The survey highlights a range of symptoms beyond constipation, including mental health concerns and financial burdens. The findings aim to enhance understanding between patients and healthcare providers regarding IBS-C and advocate for improved treatment dialogues. This survey involved over 280 participants and underscores the broader health challenges associated with IBS-C.
Read more →ARDX▲ +5%on this newsshared move
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH (tenapanor) at the American Society of Nephrology’s Kidney Week
Ardelyx, Inc. presented new data at the American Society of Nephrology's Kidney Week supporting its first-in-class phosphate absorption inhibitor, XPHOZAH (tenapanor). The studies highlighted XPHOZAH's efficacy in reducing serum phosphorus levels in adults with chronic kidney disease on dialysis. The company's presentations included analyses showing improved phosphate control correlated with lower cardiovascular risk markers. Ardelyx aims to provide innovative treatments for conditions like hyperphosphatemia affecting kidney disease patients.
Read more →ARDXARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Ardelyx, Inc. on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board. The complaint follows a significant drop in Ardelyx’s stock price after the company disclosed it would not apply to include XPHOZAH in the TDAPA program, contrary to prior statements made by its executives. Investors are being encouraged to reach out to the law firm for more information on the developments regarding their rights and the ongoing investigation.
Read more →ARDXArdelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
Ardelyx, Inc. has launched a new podcast titled 'Gut Matters: Discoveries and Innovations' aimed at the irritable bowel syndrome with constipation (IBS-C) patient community. Hosted by Johannah Ruddy and Dr. Andrea Shin, the podcast will feature monthly discussions with patients, caregivers, and experts to address the challenges of IBS-C. By providing a supportive platform, the podcast intends to offer education, insights, and a sense of community to those affected by the condition. This initiative aligns with Ardelyx's mission to empower patients managing IBS-C.
Read more →ARDXArdelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
Ardelyx, Inc. has launched the Derek Forfang Patient Advocate Award to recognize advocates dedicated to improving health outcomes for those with chronic kidney disease (CKD). The award, named after a beloved member of the CKD community who passed away, aims to celebrate the contributions of individuals who raise awareness and advocate for patients. Nominations are now open and will be evaluated by the Derek Forfang Patient Advisory Council. Recipients will receive financial awards to support their advocacy efforts.
Read more →ARDXArdelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
Ardelyx, Inc. has announced a scheduled conference call on October 31, 2024, to discuss its third quarter financial results and provide a business update. The company, known for its focus on innovative medicines, has two commercially approved products in the United States. Additionally, Ardelyx has collaborations for its products in different international markets, showcasing its global outreach.
Read more →ARDXArdelyx to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
Ardelyx, Inc. announced plans to present new data on its first-in-class phosphate absorption inhibitor, XPHOZAH (tenapanor), at the ASN Kidney Week 2024 in San Diego. The presentations will include findings on the drug's efficacy in reducing serum phosphate levels in adults with chronic kidney disease on dialysis. XPHOZAH is already approved for use as an add-on therapy for patients who do not respond adequately to phosphate binders. Alongside the presentations, Ardelyx will host a discussion on hyperphosphatemia management featuring leading experts in the field.
Read more →ARDXArdelyx, Inc. Class Action: Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 – ARDX
Levi & Korsinsky, LLP has announced a class action lawsuit against Ardelyx, Inc. (NASDAQ: ARDX) for alleged securities fraud affecting investors between October 31, 2023, and July 1, 2024. The complaint accuses the defendants of making false statements and concealing actions that allegedly inflated Ardelyx's stock price, causing financial harm to investors who acquired shares at these inflated prices. Investors have until October 15, 2024, to apply to be lead plaintiffs in the case. Participation in the suit does not require any out-of-pocket costs.
Read more →ARDXArdelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
Ardelyx announced the publication of a review article focused on irritable bowel syndrome with constipation (IBS-C) in the U.S., which provides a thorough overview of treatment options and highlights the challenges faced by patients. The article emphasizes the relationship between patients and healthcare providers in the management of the condition. It identifies IBSRELA as a key FDA-approved treatment and discusses the significant burden IBS-C imposes on patients, affecting their quality of life and economic stability. The publication aims to raise awareness and improve understanding of the complexities involved in diagnosing and treating IBS-C.
Read more →ARDXArdelyx, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 15, 2024 Deadline to file Lead Plaintiff Motion.
The Portnoy Law Firm has announced a class action suit on behalf of Ardelyx, Inc. investors who purchased securities during the defined Class Period from October 31, 2023, to July 1, 2024. Investors have until October 15, 2024, to file a lead plaintiff motion. This follows a significant stock price drop after Ardelyx announced it would not proceed with including XPHOZAH in TDAPA, contrary to previous statements made by the company's executives.
Read more →ARDXArdelyx, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights – ARDX
A class action lawsuit has been initiated against Ardelyx, Inc. concerning alleged securities fraud that affected investors from October 31, 2023, to July 1, 2024. The complaint claims that the defendants engaged in deceptive practices that inflated the company's stock price, causing financial harm to shareholders. Interested investors can join the suit at no out-of-pocket expense and have until October 15, 2024, to apply as lead plaintiff. Levi & Korsinsky, LLP is leading the case, highlighting their extensive expertise in securities litigation.
Read more →ARDXArdelyx, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 15, 2024 to Discuss Your Rights – ARDX
Ardelyx, Inc. is facing a securities fraud class action lawsuit concerning allegations of misleading statements and deceptive practices that inflated its stock price. The complaint highlights a class period from October 31, 2023, to July 1, 2024, during which shareholders are encouraged to register for potential recovery. The Gross Law Firm is facilitating this process and has set a deadline of October 15, 2024, for shareholders seeking lead plaintiff status. Investors are advised to act swiftly to understand their rights and participate in the case.
Read more →ARDXArdelyx to Participate at the 2024 Cantor Global Healthcare Conference
Ardelyx, Inc. announced its participation in the 2024 Cantor Global Healthcare Conference, scheduled for September 19, 2024. Chief Financial and Operations Officer Justin Renz will engage in a fireside chat during the event at 9:10 A.M. Eastern Time in New York City. Ardelyx has a mission to deliver innovative medicines and currently markets two products in the U.S., with further international distribution agreements in place.
Read more →ARDXArdelyx, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 15, 2024 Deadline to file Lead Plaintiff Motion
The Portnoy Law Firm has notified Ardelyx, Inc. investors about a class action lawsuit concerning securities purchased between October 31, 2023, and July 1, 2024. The lawsuit arises from Ardelyx's unexpected decision not to apply for including XPHOZAH in TDAPA, leading to a significant drop in the company’s stock price. Investors now have until October 15, 2024, to submit a lead plaintiff motion. The law firm is offering no-cost consultations for affected investors.
Read more →ARDXArdelyx, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights – ARDX
Ardelyx, Inc. is under threat of a class action lawsuit alleging securities law violations. Filed by Levi & Korsinsky, the lawsuit pertains to claims that between October 31, 2023, and July 1, 2024, the company engaged in deceptive practices that misled investors. According to the complaint, these actions caused investors to buy Ardelyx securities at inflated prices, resulting in financial losses. Investors are encouraged to contact Levi & Korsinsky to discuss their rights and potential participation in the lawsuit.
Read more →ARDXARDELYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announced a class action lawsuit against Ardelyx, Inc., representing investors who acquired securities from October 31, 2023, to July 1, 2024. The claim arises from Ardelyx's earlier statements regarding its intent to apply for the inclusion of XPHOZAH in TDAPA, which were contradicted by a July 2 disclosure of its decision not to proceed. Following this revelation, Ardelyx's stock experienced a significant decline of 30.25%. Investors have until October 15, 2024, to act as lead plaintiffs in the lawsuit.
Read more →ARDX▲ +5.8%on this news
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
Ardelyx, Inc. has appointed Eric Foster as its new Chief Commercial Officer, bringing over 23 years of experience in the biotech and pharmaceutical industries. Foster will lead the commercial strategies for Ardelyx's two first-in-class medicines, IBSRELA and XPHOZAH, while also supporting future product launches. His previous roles, including at Amgen and Horizon Therapeutics, highlight his successful track record in developing market strategies. Ardelyx aims to enhance its commercial execution and broaden patient access to its innovative treatments.
Read more →ARDXArdelyx Reports Second Quarter 2024 Financial Results and Provides Business Update IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2
Ardelyx, Inc. reported its financial results for the second quarter of 2024, highlighting strong revenue growth from its products IBSRELA and XPHOZAH, with net product sales of $35.4 million and $37.1 million, respectively. The company ended the quarter with approximately $186 million in cash and investments and foresees significant market share potential for IBSRELA. However, Ardelyx is facing challenges related to upcoming CMS regulations that may restrict access to XPHOZAH, contributing to increased expenses. The company is actively working to address these challenges while promoting its innovative treatments.
Read more →ARDXArdelyx Announces Publication of Two Plain Language Summaries from XPHOZAH (tenapanor) Clinical Trials in Current Medical Research and Opinion
Ardelyx has published plain language summaries of clinical trial results for XPHOZAH (tenapanor), aimed at helping adult patients with chronic kidney disease on dialysis understand treatment options for managing elevated phosphate levels. These summaries, featured in Current Medical Research and Opinion, provide accessible insights into the safety and efficacy of XPHOZAH, which is the first phosphate absorption inhibitor approved for this patient population. The clinical trials, NORMALIZE and OPTIMIZE, highlight XPHOZAH's unique mechanism and its potential to improve patient outcomes. However, there are noted adverse effects, particularly diarrhea, which is common among users.
Read more →ARDXArdelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Ardelyx, Inc. has announced plans to hold a conference call on August 1, 2024, to discuss its financial results from the second quarter of 2024. The company, known for developing innovative medicines, has two approved products in the U.S. and is actively working on expanding its global reach. Investors can participate in the call via phone or listen to the live webcast on the company's website.
Read more →ARDX▼ -7.4%on this newsshared move
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
Ardelyx, in partnership with AAKP and NMQF, has filed a lawsuit against CMS over the inclusion of XPHOZAH in the ESRD PPS, claiming it will restrict patient choice and access to medications. The lawsuit argues that this plan violates regulatory authority established under the Medicare Improvements for Patients and Providers Act. XPHOZAH, recently approved for CKD patients on dialysis, offers a critical treatment option for preventing elevated serum phosphorus levels. The plaintiffs seek to prevent the execution of CMS’s plan, which is set to impact patients starting January 1, 2025.
Read more →ARDX▲ +14%on this news
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
Ardelyx, Inc. has presented new data on the educational needs related to irritable bowel syndrome with constipation (IBS-C) management. The findings, displayed at the 2024 AANP Annual Conference, reveal notable differences in practice and treatment approaches among nurse practitioners, physician assistants, and physicians. It emphasizes the importance of tailored educational initiatives to address the specific requirements of various healthcare specialties, particularly in the context of IBS-C diagnosis and management. This data contributes to understanding and improving care for the millions affected by IBS-C in the United States.
Read more →ARDXArdelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. announced the granting of stock options and Restricted Stock Units (RSUs) to new non-executive employees as employment inducements on May 23, 2024. A total of 210,000 shares in stock options and 179,050 RSUs were awarded, with options priced at $7.44 per share. The stock options and RSUs will vest over a four-year period, incentivizing new hires to commit long-term to Ardelyx. The company continues to focus on developing and commercializing innovative medicines to meet medical needs.
Read more →ARDXArdelyx to Participate at the 2024 Jefferies Global Healthcare Conference
Ardelyx, Inc. has announced that its President and CEO, Michael Raab, along with CFO Justin Renz, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on June 5, 2024. The event will focus on the company's innovative medicines and ongoing commercial success. Ardelyx is known for its products IBSRELA and XPHOZAH, targeting significant medical needs. The conference provides a platform to enhance investor relations and showcase Ardelyx's developments in the biopharmaceutical sector.
Read more →ARDXArdelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA (tenapanor), a First-In-Class Treatment for IBS-C in Adults
Ardelyx, Inc. announced the presentation of additional positive clinical data for its first-in-class treatment, IBSRELA (tenapanor), at the 2024 Digestive Disease Week Conference. The data includes findings that demonstrate the drug's efficacy in adult patients with irritable bowel syndrome with constipation (IBS-C), including favorable results among Hispanic patients. Key analyses indicated the drug's effectiveness irrespective of previous IBS treatments. However, safety concerns persist, particularly regarding its use in pediatric patients due to dehydration risks.
Read more →ARDXArdelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH (tenapanor)
Ardelyx, Inc. presented additional positive clinical data for XPHOZAH (tenapanor) at the NKF 2024 Spring Clinical Meetings. This first-in-class phosphate absorption inhibitor is approved for adults with chronic kidney disease on dialysis. Findings from various studies showed that XPHOZAH improves serum phosphate control and enhances patient adherence to treatment. However, diarrhea remains a significant side effect, warranting caution in some patients.
Read more →ARDXArdelyx to Present Additional Data Supporting First-In-Class IBSRELA (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
Ardelyx, Inc. announced the presentation of additional data supporting its first-in-class drug, IBSRELA (tenapanor), at the 2024 Digestive Disease Week Conference. This drug is FDA-approved for treating irritable bowel syndrome with constipation (IBS-C) in adults. The company will present findings from posthoc analyses of Phase 3 studies regarding the efficacy of tenapanor in different patient demographics. Furthermore, Ardelyx will sponsor a Product Theater discussing the drug's mechanism of action and clinical considerations in managing IBS-C.
Read more →ARDXArdelyx Reports First Quarter 2024 Financial Results and Provides Business Update Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 mi
Ardelyx, Inc. reported its financial results for Q1 2024, highlighting a total of $45.6 million in product-related revenue, driven primarily by sales of IBSRELA and the newly launched XPHOZAH. The company's cash position remains robust at approximately $203 million, allowing for ongoing investment in growth. Notably, IBSRELA sales grew significantly, reaching $28.4 million, while XPHOZAH achieved $15.2 million in net sales in its first full quarter post-launch. However, the company also experienced a net loss of $26.5 million during this period due to rising expenses related to commercialization efforts.
Read more →ARDXArdelyx to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
Ardelyx, Inc. announced the presentation of additional data supporting their drug XPHOZAH (tenapanor) at the National Kidney Foundation 2024 Spring Clinical Meetings. XPHOZAH is the first phosphate absorption inhibitor approved for adults with chronic kidney disease on dialysis. The drug aims to reduce serum phosphorus levels in patients who cannot adequately respond to other phosphate therapies. Alongside presentations, Ardelyx is also sponsoring discussions on rethinking hyperphosphatemia management.
Read more →ARDXArdelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Ardelyx, Inc. will hold a conference call on May 2, 2024, to discuss its financial results for the first quarter of 2024 and provide a business update. The company has two commercial products approved in the U.S. and additional candidates in its early-stage pipeline. This engagement with investors suggests continued activity and focus on their pharmaceutical initiatives.
Read more →ARDXArdelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
Ardelyx, Inc. has appointed Mike Kelliher as Executive Vice President of Corporate Development and Strategy, a newly created position reflecting the company's pivotal growth phase. Kelliher joins with over 20 years of industry experience, notably from Horizon Therapeutics, where he contributed to significant company growth through mergers and acquisitions. Ardelyx has recently launched two innovative medicines, enhancing its focus on addressing unmet medical needs. The leadership change aims to solidify the company's future direction and expand its strategic capabilities.
Read more →ARDXArdelyx to Participate at the Cowen 44th Annual Health Care Conference
Ardelyx, Inc. (Nasdaq: ARDX) announced its participation in the Cowen 44th Annual Health Care Conference, set for March 5, 2024. Chief Commercial Officer Susan Rodriguez will be involved in a panel discussion focused on Cardiorenal topics. The event reflects Ardelyx's commitment to address unmet medical needs through its innovative medicines. Live webcasts will be accessible, and a replay will be available for 30 days post-event.
Read more →ARDXArdelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue 2024 net
Ardelyx, Inc. reported its financial results for Q4 and FY 2023, highlighting strong sales performance for its IBSRELA and XPHOZAH products. IBSRELA ended FY 2023 with $80.1 million in net product sales, reflecting a 26% growth in Q4. The company expects continued growth in 2024, with projected sales of IBSRELA between $140 and $150 million. While Ardelyx maintains a solid financial position with $184.3 million in cash, it also recorded a significant net loss for the year and increased operational costs.
Read more →ARDX▲ +6.4%on this news
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Ardelyx, Inc. announced that it will hold a conference call on February 22, 2024, to discuss its fourth quarter and full year financial results for 2023. The call will provide updates on the company's business and is part of its commitment to transparency with investors. Ardelyx has two commercial products in the U.S. and continues to develop its pipeline with various partnerships for international commercialization.
Read more →ARDX▲ +32.8%on this news· ran to +48% by day 1
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
Ardelyx, Inc. reported substantial commercial growth in 2023, marking its first full year as a commercial entity with significant sales of its products, IBSRELA and XPHOZAH. The company anticipates IBSRELA will achieve over $1.0 billion in peak U.S. sales. Ardelyx plans to enhance its sales efforts and expand internationally in 2024, while also managing initial demand for XPHOZAH, recently approved by the FDA. The company reported a solid financial position with approximately $184 million in cash reserves, enabling continued investment in growth and patient services.
Read more →ARDXArdelyx to Provide Company Update on IBSRELA and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Ardelyx, Inc. announced it will host a live event on January 8, 2024, featuring an update on its FDA-approved treatment IBSRELA for irritable bowel syndrome with constipation (IBS-C). The event will include a discussion with Dr. Philip Schoenfeld, focusing on the current IBS-C treatment landscape. IBSRELA is contraindicated for children under six due to dehydration risks, and severe diarrhea was noted as a common adverse reaction. The event underscores Ardelyx's ongoing commitment to addressing unmet medical needs in gastrointestinal conditions.
Read more →ARDXArdelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
Ardelyx, Inc. will participate in the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The session will include a fireside chat, accessible via a live webcast on the company's Investor Relations website. Ardelyx, which aims to address significant medical needs, has two approved products in the U.S. and is advancing its pipeline, including international collaborations.
Read more →ARDX▲ +5.6%on this news
Ardelyx Announces Departure of Board Member
Ardelyx, Inc. announced the departure of Geoffrey Block, MD, from its Board of Directors after nearly five years of service. Dr. Block thanked the leadership team for their accomplishments and expressed pride in Ardelyx's position following the FDA approval of XPHOZAH, a new option for patients with chronic kidney disease. The company continues to progress with its commercial products and pipeline candidates as it enters a new phase of development and growth.
Read more →ARDXArdelyx to Participate at the Jefferies London Healthcare Conference
Ardelyx, Inc. will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2023. The event will be accessible online, with a replay available for 30 days. Ardelyx is dedicated to developing first-in-class medicines and currently has two commercial products, IBSRELA and XPHOZAH, approved in the U.S. The company is also expanding its reach with international partnerships for its product tenapanor.
Read more →ARDXArdelyx Announces XPHOZAH (tenapanor) Now Available in the United States
Ardelyx, Inc. has announced that XPHOZAH (tenapanor), the first FDA-approved phosphate absorption inhibitor, is now available for shipment to pharmacies. This medication is aimed at reducing serum phosphorus in adults with chronic kidney disease on dialysis who have inadequate responses to phosphate binders. Accompanying XPHOZAH's launch is the ArdelyxAssist program, which supports patients in accessing this new treatment. The company emphasizes their commitment to patient support and product innovation, despite potential side effects associated with the treatment.
Read more →ARDXArdelyx Shares Positive Data from Studies of XPHOZAH (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
Ardelyx, Inc. showcased positive findings on its first-in-class phosphate absorption inhibitor, XPHOZAH (tenapanor), at ASN Kidney Week 2023. The drug, recently approved by the FDA, demonstrates a unique mechanism to reduce serum phosphorus in chronic kidney disease patients on dialysis. The presentation highlighted improved patient quality of life and adherence to treatment through educational approaches. Safety analyses indicated that tenapanor has a favorable profile compared to traditional treatments, despite a notable occurrence of diarrhea among patients.
Read more →ARDX▲ +9.1%on this newsshared move
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA Net Sales Revenue Guidance
Ardelyx, Inc. reported strong financial results for Q3 2023, highlighting significant revenue growth of its IBSRELA product, generating $22.3 million in net sales. The company anticipates full-year U.S. net sales revenue for IBSRELA to be between $76 million and $78 million. Additionally, the FDA recently approved XPHOZAH, enhancing the company's product offerings. Ardelyx's cash and investments surged to approximately $218.1 million as of October, indicating strong financial stability.
Read more →ARDXArdelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
Ardelyx has announced positive data regarding its treatment IBSRELA (tenapanor) for patients with irritable bowel syndrome with constipation (IBS-C), which will be presented at the ACG 2023 annual meeting. The findings demonstrate a quick onset of symptom relief and show that response rates improve with continued treatment. Safety warnings highlight risks in pediatric patients and common adverse effects including diarrhea. The company aims to enhance awareness and understanding of IBSRELA's benefits among physicians and patients.
Read more →ARDX▲ +13.3%on this newsshared move
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
Ardelyx, Inc. announced it will hold a conference call on October 31, 2023, to review its financial results for the third quarter. The call will start at 8:00 a.m. Eastern Time and will also provide a business update. The company continues to focus on developing innovative medicines and has two approved products in the U.S., along with promising pipeline candidates. Ardelyx is actively expanding its presence for tenapanor in various global markets.
Read more →ARDXArdelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
Ardelyx, Inc. has announced amendments to its debt financing agreement with SLR Capital Partners, allowing access to an additional $50 million in capital. The company anticipates drawing $22.5 million of this additional financing in October to support its commercial initiatives for recently FDA-approved products IBSRELA and XPHOZAH. The amendment also provides an extended interest-only period until December 31, 2026, which is expected to strengthen Ardelyx's financial position and operational capabilities.
Read more →ARDXArdelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA Net Sales Revenue Guidance Continued successful launch of IBSRELA, with Q3 net sales revenue of $22.3 million Company currently expects 2
Ardelyx, Inc. reported its third-quarter financial results for 2023, highlighting a strong performance for its product IBSRELA, which saw net sales revenue rise to $22.3 million. Following FDA approval, the company is preparing for the launch of XPHOZAH, anticipated to be available in early November. Ardelyx's cash position improved significantly, reaching approximately $218.1 million. However, increased R&D and administrative expenses were noted as the company prepares for higher commercialization activities.
Read more →ARDXArdelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
Ardelyx, Inc. has announced upcoming presentations at the ASN Kidney Week 2023 focused on tenapanor, an investigational phosphate absorption inhibitor for hyperphosphatemia. The company will showcase four posters detailing data from two trials involving U.S. patients undergoing maintenance dialysis. Additionally, Kyowa Kirin, a collaboration partner for tenapanor in Japan, will present results from two Phase 3 studies in similar patient cohorts. These presentations underscore the potential benefits of tenapanor in managing hyperphosphatemia.
Read more →ARDXArdelyx Shares Preliminary Data on Use of IBSRELA (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
Ardelyx, Inc. has presented preliminary data on the use of IBSRELA (tenapanor) in pediatric patients with irritable bowel syndrome with constipation (IBS-C) at the NASPGHAN 2023 Annual Meeting. The ongoing Phase 3 R-Ally Trial is evaluating the safety and efficacy of tenapanor in adolescents aged 12 to 17. The data shared indicates no serious adverse events reported among trial participants so far, but safety and effectiveness in patients under 18 have not yet been fully established. This data marks an important step for Ardelyx in addressing the unmet medical needs of children suffering from IBS-C.
Read more →ARDXArdelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
Ardelyx, Inc. has announced the publication of positive results from the T3MPO-3 long-term open-label safety trial of its drug IBSRELA (tenapanor) for treating irritable bowel syndrome with constipation (IBS-C). The study revealed an acceptable safety profile consistent with previous trials, with important findings published in the Journal of Neurogastroenterology and Motility. However, the drug is contraindicated in young children due to risks of serious dehydration. Despite some treatment-emergent adverse events reported, the results support the continued growth of IBSRELA as a therapy for IBS-C.
Read more →ARDXArdelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA (tenapanor) for IBS-C at GHAPP 2023
Ardelyx, Inc. presented promising new data on its product, IBSRELA (tenapanor), during the GHAPP 2023 conference. The findings suggest significant improvements in abdominal symptom scores and treatment satisfaction among patients with Irritable Bowel Syndrome with Constipation (IBS-C). Additionally, the analyses reinforce the drug's safety and efficacy across diverse patient groups. However, there are notable safety warnings, especially regarding dehydration risks in pediatric patients.
Read more →ARDXArdelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Ardelyx, Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023, showcasing its commitment to innovative medicine. The CEO, Mike Raab, will lead the presentation amid growing interest in Ardelyx's pipeline, notably the product XPHOZAH for CKD patients and ongoing developments in other therapeutic areas. The event underscores Ardelyx's mission to address significant unmet medical needs.
Read more →ARDX▲ +5.2%on this news
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance Continued successful launch of IBSRELA, with Q2 net sales revenue of $18.3 million Company currently expects 2023
Ardelyx, Inc. reported its Q2 2023 financial results, highlighting significant net sales revenue from its product IBSRELA at $18.3 million, showcasing a 61% growth from Q1. The company announced expectations for full-year IBSRELA revenues between $72 million and $77 million, reflecting an optimistic market trajectory. Looking ahead, Ardelyx is preparing for the potential launch of its drug XPHOZAH in Q4 2023, pending FDA approval. Despite the positive revenue performance, Ardelyx reported a net loss of $17.1 million for the quarter.
Read more →ARDXArdelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
Ardelyx, Inc. will hold a conference call on August 2, 2023, at 8:00 a.m. ET to discuss its second quarter 2023 financial results and business updates. The call will be available through audio webcast on the company's website, with a replay option for 30 days. Ardelyx is known for its innovative medicines, including IBSRELA and XPHOZAH, aimed at addressing significant unmet medical needs, particularly in chronic kidney disease.
Read more →ARDXArdelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
Ardelyx, Inc. announced that its CEO, Mike Raab, will present at the H.C. Wainwright 2nd Annual Kidney Conference on July 25, 2023. The company is focused on innovative treatments for significant unmet medical needs in kidney health, with successful Phase 3 trials for its novel product candidate, XPHOZAH. Ardelyx is also developing other treatments for conditions associated with chronic kidney disease. The event will be accessible via webcast, and a replay will be available for 30 days following the presentation.
Read more →ARDXArdelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
Ardelyx, Inc. has announced that its New Drug Application (NDA) for tenapanor has been accepted for review by China's National Medical Products Administration, targeting serum phosphorus control in chronic kidney disease patients on hemodialysis. This acceptance prompts a $2 million milestone payment from its collaboration partner Fosun Pharma, with potential NDA approval expected by the end of 2024. Ardelyx's collaboration with Fosun aims to expand its innovative therapy offerings in the Chinese market, aligning with its mission to address significant unmet medical needs.
Read more →ARDXArdelyx to Present at the Jefferies 2023 Healthcare Conference
Ardelyx, Inc. will have its president and CEO, Mike Raab, participate in a fireside chat at the Jefferies Healthcare Conference on June 7, 2023. The event will take place in New York City, and individuals can access the live webcast through Ardelyx's investor website. The company is known for its first approved product, IBSRELA, and is actively developing several other candidates for significant medical conditions.
Read more →ARDX▼ -11.9%on this news
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH (tenapanor)
Ardelyx, Inc. announced that the FDA has accepted its resubmission of a New Drug Application for XPHOZAH (tenapanor), aimed at controlling serum phosphate in adult patients with chronic kidney disease on dialysis. The FDA's review is classified as a class 2, leading to a six-month review period ending on October 17, 2023. Ardelyx is optimistic about launching XPHOZAH in the fourth quarter of 2023, following FDA approval. The NDA is backed by three successful Phase 3 trials demonstrating the drug's efficacy and safety.
Read more →ARDXArdelyx Presents Positive Data at DDW 2023 on IBSRELA (tenapanor), a First-In-Class Treatment for IBS-C in Adults
Ardelyx, Inc. has presented positive results regarding its first-in-class treatment IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) at the 2023 Digestive Disease Week Conference. The Phase 3 T3MPO-2 trial data indicates that patients treated with IBSRELA experienced meaningful reductions in abdominal symptoms, which correlated strongly with patient-reported satisfaction. The innovative mechanism of action of IBSRELA highlights its potential role in addressing a significant unmet medical need in IBS-C. However, there are important safety concerns regarding contraindications in certain age groups.
Read more →ARDX▲ +5.4%on this news
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
Ardelyx, Inc. reported its first-quarter financial results for 2023, highlighting a strong launch of its IBSRELA medication, which generated $11.4 million in sales. The company also resubmitted its New Drug Application for XPHOZAH, signaling potential market entry in the latter half of the year pending FDA approval. Ardelyx's cash reserves exceeded $130 million, positioning the firm for growth and development, while it also announced a licensing deal with METiS Therapeutics. However, the company continues to incur losses and faces challenges with rising operational costs and safety concerns related to IBSRELA usage in children.
Read more →ARDXArdelyx Announces Additional Data Supporting First-In-Class IBSRELA (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
Ardelyx, Inc. announced that additional data supporting its drug IBSRELA (tenapanor) for adults with IBS-C will be presented at the 2023 Digestive Disease Week Conference. The company will showcase patient-reported treatment satisfaction and abdominal pain score improvements associated with the treatment. Additionally, a sponsored Product Theater will explore IBSRELA's novel mechanism of action and efficacy data from clinical trials. IBSRELA is indicated for treating IBS-C in adults but carries important safety warnings regarding its contraindications in pediatric populations.
Read more →ARDXArdelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Ardelyx, Inc. will hold a conference call on May 3, 2023, to discuss its first quarter financial results and provide a business update. The company aims to address unmet medical needs with its innovative therapies. Key products include IBSRELA® and the development of XPHOZAH® for chronic kidney disease. The call will be accessible via phone and webcast, and an archive will be available for later viewing.
Read more →ARDXArdelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH (tenapanor)
Ardelyx, Inc. has resubmitted a New Drug Application (NDA) for XPHOZAH (tenapanor) to the FDA, aiming to control serum phosphate levels in adult patients with chronic kidney disease undergoing dialysis. The resubmission follows a robust development program, including three successful Phase 3 trials with over 1,200 participants. The company anticipates receiving an Acknowledgment of Receipt letter from the FDA by mid-May, which will confirm the completion of the resubmission and provide a review goal date.
Read more →ARDXArdelyx Reports First Quarter 2023 Financial Results and Provides Business Update Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on
Ardelyx, Inc. reported its financial results for the first quarter of 2023, highlighting a successful launch of IBSRELA with $11.4 million in sales. The company also resubmitted its New Drug Application for XPHOZAH, with plans for launch in the latter half of 2023 pending FDA approval. Ardelyx ended the quarter with over $130 million in cash, despite reporting a net loss of $26.8 million. The firm continues to focus on expanding market share for IBSRELA while preparing for future product launches.
Read more →ARDXArdelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
Ardelyx, Inc. announced positive results from multiple presentations at the National Kidney Foundation 2023 Spring Clinical Meetings regarding XPHOZAH, a phosphate absorption inhibitor. Data indicated that XPHOZAH effectively lowers serum phosphate levels and iFGF23 in chronic kidney disease patients on maintenance dialysis. Additionally, the results from three Phase 3 trials reinforce the potential benefits of XPHOZAH across different patient demographics. Diarrhea is noted as a common adverse effect, but the overall safety profile is deemed acceptable.
Read more →ARDXArdelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales Resubmission of XPHOZAH New
Ardelyx, Inc. reported its fourth quarter and full year 2022 financial results, highlighting the successful launch of its IBSRELA product, resulting in $15.6 million in net sales. The company aims to resubmit its NDA for XPHOZAH in early Q2 2023, following positive feedback from the FDA. Ardelyx finished 2022 with $123.9 million in cash and investments, positioning itself for future growth. The CEO emphasized ongoing commitment to addressing significant unmet medical needs with their innovative products.
Read more →ARDXArdelyx Publishes First Environmental, Social and Governance (ESG) Report
Ardelyx, Inc. has published its first Environmental, Social and Governance (ESG) Report detailing its sustainability efforts for 2022. The report highlights the company's initiatives like the ArdelyxAssist™ patient services program and substantial donations towards educational programs. Ardelyx emphasizes its commitment to building a more equitable society while maintaining a focus on patients, employees, and community engagement. The company's broader strategy includes ongoing developments in medicines targeting unmet medical needs.
Read more →ARDXArdelyx to Participate at the Cowen 43rd Annual Health Care Conference
Ardelyx, Inc. will participate in the Cowen 43rd Annual Health Care Conference, scheduled for March 6, 2023, where its CEO Mike Raab will join a panel discussion focused on GI/Microbiome. This participation highlights the company's commitment to addressing unmet medical needs through innovative therapies. Ardelyx is known for its first approved product, IBSRELA, and is actively advancing its drug candidates, including XPHOZAH and RDX013, which target serious conditions in kidney patients. The event will be accessible via webcast, and a replay will be available for 30 days post-event.
Read more →ARDXArdelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
Ardelyx, Inc. announced it will hold a conference call on March 2, 2023, to discuss its fourth quarter and full year 2022 financial results, along with a business update. The biopharmaceutical company continues to focus on innovative medicines, notably with an approved product, IBSRELA, and the development of XPHOZAH aimed at treating chronic kidney disease. The company has achieved successful Phase 3 trials and is engaged in international partnerships for broader commercial reach.
Read more →ARDXArdelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4 30 p.m. Eastern Time today
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4 30 p.m. Eastern Time today WALTHAM, Mass., November 3, 2022 - Ardelyx, Inc. (Nasdaq ARDX), a biopharmaceutical company founded with a mission to discover, develo
Read more →ARDX▲ +7.2%on this news
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4 30 p.m. Eastern Time today
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights Conference call scheduled for 4 30 p.m. Eastern Time today WALTHAM, Mass., Aug 4, 2022 - Ardelyx, Inc. (Nasdaq ARDX), a biopharmaceutical company founded with a mission to discover, develop an
Read more →ARDX▼ -7.7%on this news· ran to -20% by day 3
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Conference Call Scheduled for 4 30 PM Eastern Time Today
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights Conference Call Scheduled for 4 30 PM Eastern Time Today WALTHAM, Mass., May 5, 2022 - Ardelyx, Inc. (Nasdaq ARDX), a biopharmaceutical company founded with a mission to discover, develop and c
Read more →ARDXArdelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Company Advancing Toward Launch of IBSRELA in April 2022 Conference Call scheduled for 4 30 PM Eastern Time
Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Company Advancing Toward Launch of IBSRELA in April 2022 Conference Call scheduled for 4 30 PM Eastern Time WALTHAM, Mass., Feb 28, 2022 -- Ardelyx, Inc. (Nasdaq ARDX), a biopharmaceutic
Read more →ARDXArdelyx Reports Third Quarter 2021 Financial Results FREMONT, Calif. and
Ardelyx Reports Third Quarter 2021 Financial Results FREMONT, Calif. and WALTHAM, Mass., November 12, 2021 -- Ardelyx, Inc. (Nasdaq ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve t
Read more →ARDX▼ -5.3%on this news
Ardelyx Reports Second Quarter 2021 Financial Results FREMONT, Calif.
Ardelyx Reports Second Quarter 2021 Financial Results FREMONT, Calif. WALTHAM, Mass., August 13, 2021 -- Ardelyx, Inc. (Nasdaq ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatm
Read more →ARDXARDELYX INVESTIGATION: Block & Leviton Investigates Ardelyx for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Ardelyx, Inc. (NASDAQ: ARDX) for potential securities law violations. Investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, please
Read more →ARDXArdelyx, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Ardelyx, Inc. (NASDAQ: ARDX) investors that acquired shares between August 6, 2020 and July 19, 2021. Investors have until September 28,
Read more →ARDX▼ -8.1%on this news
Ardelyx, Inc. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, July 22, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Inves
Read more →ARDXArdelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights FREMONT, Calif.
Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights FREMONT, Calif. WALTHAM, Mass., May 6, 2021 -- Ardelyx, Inc. (Nasdaq ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people
Read more →ARDXArdelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights Company well positioned for PDUFA date of
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights Company well positioned for PDUFA date of April 29, 2021 and the potential launch of tenapanor FREMONT, Calif./ WALTHAM, Mass., March 8, 2021 -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmace
Read more →ARDXArdelyx Reports Third Quarter 2020 Financial Results and Business Highlights Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for
Ardelyx Reports Third Quarter 2020 Financial Results and Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments FREMONT, Calif., November 5, 2020 -
Read more →ARDXArdelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to co
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidn
Read more →ARDXArdelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments FREMONT, Calif., May 7, 2020 -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized bioph
Read more →ARDXArdelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights FREMONT, Calif., March 06, 2020 -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for peo
Read more →ARDXForward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and e
Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor
Read more →ARDXArdelyx Reports Third Quarter 2019 Financial Results and Recent Highlights PHREEDOM clinical trial to read out this quarter
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights PHREEDOM clinical trial to read out this quarter FREMONT, Calif., November 6, 2019 -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines
Read more →ARDXArdelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights AMPLIFY clinical trial to read out 3Q19 PHREEDOM clinical trial to read out 4Q19
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights AMPLIFY clinical trial to read out 3Q19 PHREEDOM clinical trial to read out 4Q19 FREMONT, Calif., August 9, 2019 -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focus
Read more →ARDXArdelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights Two Pivotal Phase 3 readouts in 2H 2019
Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights Two Pivotal Phase 3 readouts in 2H 2019 FREMONT, Calif., May 7, 2019 -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to i
Read more →ARDXArdelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights  Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia
Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif., March 6, 2019 -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing
Read more →ARDXTo the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management m
BREAKTHROUGH SCIENCE FOR BETTER HEALTH J.P. Morgan Healthcare Conference 2019 Exhibit 99.1 To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current belief
Read more →ARDXArdelyx Reports Third Quarter 2018 Financial Results and Recent Highlights Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif., Nov. 7, 2018 -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights and financia
Read more →ARDXArdelyx Reports Second Quarter 2018 Financial Results and Recent Highlights Operating Runway Extended to Mid 2020 Preparing to Submit NDA for Tenapanor in IBS-C in Early Q4 2018 Conference Call to be Held Today at 4:30 p
Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights Operating Runway Extended to Mid 2020 Preparing to Submit NDA for Tenapanor in IBS-C in Early Q4 2018 Conference Call to be Held Today at 4:30 p.m. ET FREMONT, Calif., Aug. 7, 2018 -- Ardelyx, Inc. (N
Read more →ARDXRISK FACTORS Investing in our common stock involves a high degree of risk. Before deciding whether to invest in shares of our common stock, you should carefully consider the risks described below, and all other informati
Investing in our common stock involves a high degree of risk. Before deciding whether to invest in shares of our common stock, you should carefully consider the risks described below, and all other information contained in or incorporated by reference in our other filings with th
Read more →ARDXArdelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights On Track to Submit NDA for Tenapanor in IBS-C in Second Half of 2018 Enrollment Underway in Second Registration Study of Tenapanor for H
Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights On Track to Submit NDA for Tenapanor in IBS-C in Second Half of 2018 Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia FREMONT, Calif., May 8, 2018 -- Ardelyx,
Read more →ARDXArdelyx Reports 2017 Financial Results and Appoints Industry Veteran Jan Lundberg, Ph.D. to Board of Directors Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS
Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran Jan Lundberg, Ph.D. to Board of Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif.,
Read more →ARDXArdelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress FREMONT, Calif., Nov. 7, 2017 Ardelyx, Inc. (NASDAQ: ARDX), today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017. 2017 has been
Read more →ARDXArdelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results Restructuring Aligns Resources on Execution of Late-Stage Program Milestones T3MPO-2 Phase 3 Trial Results of Tenapanor
Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results Restructuring Aligns Resources on Execution of Late-Stage Program Milestones T3MPO-2 Phase 3 Trial Results of Tenapanor for IBS-C on Track for Early Fourth Quarter; Onset-of-A
Read more →ARDXFORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and e
BREAKTHROUGH SCIENCE FOR BETTER HEALTH NASDAQ: ARDX Exhibit 99.1 FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current belie
Read more →ARDXTHE INTERSECTION OF BREAKTHROUGH SCIENCE AND BETTER HEALTH ARDELYX JPMorgan 2017 Annual Healthcare Conference NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not d
ARDELYX JPMorgan 2017 Annual Healthcare Conference FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expect
Read more →ARDXArdenwood Blvd Fremont, CA 94555 (510) 745-1700 Tele www.ardelyx.com Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress Enrollment Completed in Phase 3 Trial of Tenapanor for Hyperphosphatemia in Pa
Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress Enrollment Completed in Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with ESRD on Dialysis Conference call to be held today at 4:05 p.m. ET FREMONT, Calif., November 07, 2016 Ardelyx, Inc.
Read more →ARDXArdenwood Blvd Fremont, CA 94555 (510) 745-1700 Tele (510) 745-0493 Fax www.ardelyx.com Ardelyx Reports Second Quarter 2016 Financial Results Results from the First Phase 3 trial for Tenapanor for the Treatment of Hyperp
34175 Ardenwood Blvd Fremont, CA 94555 (510) 745-1700 Tele (510) 745-0493 Fax www.ardelyx.com Ardelyx Reports Second Quarter 2016 Financial Results Results from the First Phase 3 trial for Tenapanor for the Treatment of Hyperphosphatemia in Patients with ESRD Expe
Read more →ARDXArdenwood Blvd Fremont, CA 94555 (510) 745-1700 Tele (510) 745-0493 Fax www.ardelyx.com Ardelyx Reports First Quarter 2016 Financial Results Conference Call and Webcast Today at 4:30 p.m.
Ardelyx Reports First Quarter 2016 Financial Results Conference Call and Webcast Today at 4:30 p.m. ET FREMONT, Calif., May 9, 2016 /PRNewswire/ Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, toda
Read more →ARDXArdenwood Blvd Fremont, CA 94555 (510) 745-1700 Tele (510) 745-0493 Fax www.ardelyx.com Ardelyx Reports Fourth Quarter and Full-Year 2015 Financial Results Three Late-Stage Clinical Trials for Tenapanor Initiated in 4Q20
Ardelyx Reports Fourth Quarter and Full-Year 2015 Financial Results Three Late-Stage Clinical Trials for Tenapanor Initiated in 4Q2015 RDX022 PD Study Results Support Pivotal Phase 3 Clinical Trial Plans for Hyperkalemia in 2H2016 Conference Call and Webcast Today at 8:00 a.m.
Read more →ARDXArdenwood Blvd Fremont, CA 94555 (510) 745-1700 Tele (510) 745-0493 Fax www.ardelyx.com Ardelyx Reports Third Quarter 2015 Financial Results Two key clinical development programs accelerated, tenapanor in IBS-C and RDX02
Ardelyx Reports Third Quarter 2015 Financial Results Two key clinical development programs accelerated, tenapanor in IBS-C and RDX022 in hyperkalemia Initiation of a second Phase 3 clinical trial for tenapanor in IBS-C expected December 2015 Results of a pharmacodynamic study
Read more →Competitive Position
How ARDX ranks across every disease it competes inCompetitive Position is a premium feature
See how ARDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial